The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...
Abenacianine, a tumor-targeted fluorescent imaging agent, received fast track designation from the FDA after demonstrating ...
The FDA granted priority review to sunvozertinib for the treatment of advanced NSCLC with EGFR exon 20 mutations, based on ...
Manmeet Ahluwalia, MD, MBA, FASCO, discusses the prevalence of brain metastases in patients with primary renal cell carcinoma.
An Investigator-Initiated Study of Loncastuximab Tesirine Plus Rituximab for the Treatment of R/R FL
A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier ...
Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback